RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Oncopeptides Stock

Oncopeptides P/S 2024

Oncopeptides P/S

5.2

Ticker

ONCO.ST

ISIN

SE0009414576

WKN

A2DLU2

As of Sep 22, 2024, Oncopeptides's P/S ratio stood at 5.2, a -81.72% change from the 28.44 P/S ratio recorded in the previous year.

The Oncopeptides P/S history

Oncopeptides Aktienanalyse

What does Oncopeptides do?

Oncopeptides AB is a biopharmaceutical company specializing in the research and development of novel therapeutics for the treatment of cancer. The company was founded in 2000 in Uppsala, Sweden. Oncopeptides' research focuses on the discovery of substances that can affect specific cellular processes, inhibiting or even killing the growth of cancer cells. The company places particular emphasis on the development of drugs that can be targeted against specific types of cancer and have minimal side effects. The business model of Oncopeptides is based on licensing developed drugs to other companies or marketing their own products. This allows for faster progress in development and minimizes entrepreneurial risk. The company is divided into three different divisions, focusing on different types of cancer. The first division specializes in the treatment of multiple myeloma, the second in the treatment of solid tumors, and the third in the development of diagnostic tests for early cancer detection. The first product that Oncopeptides has brought to market is the drug Ygalo. It is used to treat patients with advanced multiple myeloma who do not respond to other therapies. Ygalo is a peptide mimetic specifically designed to inhibit the protein MCL-1, which plays a key role in cell proliferation in many types of cancer. In the second division of Oncopeptides, the company focuses on the development of drugs that can be specifically targeted against solid tumors such as lung, breast, or colorectal cancer. The protein BET inhibitor is targeted, which plays an important role in the regulation of gene expression in many types of cancer. The third division of Oncopeptides is engaged in the development of diagnostic tests that enable early detection of cancer. Both blood tests and imaging techniques are used to detect changes in the body that could indicate cancer. The focus is on the development of tests that can detect early signs of cancer, enabling timely diagnosis and treatment. Overall, Oncopeptides is a promising company specializing in the development of innovative therapeutics in cancer treatment. With its focus on specific cellular processes and targeted approaches to fighting different types of cancer, the company is on a promising path to bring more products to market that can improve the lives of many cancer patients. Oncopeptides ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Oncopeptides's P/S Ratio

Oncopeptides's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Oncopeptides's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Oncopeptides's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Oncopeptides’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Oncopeptides stock

What is the price-to-earnings ratio of Oncopeptides?

The price-earnings ratio of Oncopeptides is currently 5.2.

How has the price-earnings ratio of Oncopeptides changed compared to last year?

The price-to-earnings ratio of Oncopeptides has increased by -81.72% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Oncopeptides high compared to other companies?

Yes, the price-to-earnings ratio of Oncopeptides is high compared to other companies.

How does an increase in the price-earnings ratio of Oncopeptides affect the company?

An increase in the price-earnings ratio of Oncopeptides would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Oncopeptides affect the company?

A decrease in the price-earnings ratio of Oncopeptides would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Oncopeptides?

Some factors that influence the price-earnings ratio of Oncopeptides are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Oncopeptides pay?

Over the past 12 months, Oncopeptides paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Oncopeptides is expected to pay a dividend of 0 SEK.

What is the dividend yield of Oncopeptides?

The current dividend yield of Oncopeptides is .

When does Oncopeptides pay dividends?

Oncopeptides pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Oncopeptides?

Oncopeptides paid dividends every year for the past 0 years.

What is the dividend of Oncopeptides?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Oncopeptides located?

Oncopeptides is assigned to the 'Health' sector.

Wann musste ich die Aktien von Oncopeptides kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Oncopeptides from 9/22/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 9/22/2024.

When did Oncopeptides pay the last dividend?

The last dividend was paid out on 9/22/2024.

What was the dividend of Oncopeptides in the year 2023?

In the year 2023, Oncopeptides distributed 0 SEK as dividends.

In which currency does Oncopeptides pay out the dividend?

The dividends of Oncopeptides are distributed in SEK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Oncopeptides

Our stock analysis for Oncopeptides Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oncopeptides Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.